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Abstract
Background: The management of an enterocutaneous fistula poses a significant challenge to surgeons and is
often associated with a costly hospital stay and long-term discomfort. The use of fibrin glue in the fistula tract
has been shown to promote closure of low output enterocutaneous fistulas. Our previous nonrandomized study
demonstrated that autologous platelet-rich fibrin glue treatment significantly decreased time to fistula closure
and promoted closure rates. However, there are several limitations in the study, which may lead to bias in our
conclusion. Thus, a multicenter, randomized, controlled clinical trial is required.
Methods/Design: The study is designed as a randomized, open-label, three-arm, multicenter study in nine Chinese
academic hospitals for evaluating the efficacy and safety of fibrin glue for sealing low-output fistulas. An established
number of 171 fistula patients will undergo prospective random assignment to autologous fibrin glue, commercial
porcine fibrin sealants or drainage cessation (1:1:1). The primary endpoint is fistula closure time (defined as the interval
between the day of enrollment and day of fistula closure) during the 14-day treatment period.
Discussion: To our knowledge, this is the first study to evaluate the safety and efficacy of both autologous and
commercial fibrin glue sealing for patients with low-output volume fistulas.
Trial registration: NCT01828892. Registration date: April 2013.
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Background
An enterocutaneous fistula (ECF) still remains as one of
the most complex and challenging complications en-
countered in surgical practice [1]. Its management often
requires a costly hospital stay and multidisciplinary care
due to high morbidity and mortality induced by sepsis,
hemorrhage, malnutrition and electrolyte disturbances
[2, 3]. Staged fistula treatment involves recognition and
stabilization, anatomic definitioxn and decision, and de-
finitive operation. With sufficient time, conservative
treatment can result in spontaneous fistula closure, with
rates varying from 15 % to 71 % [4]. However, this also
results in long-term discomfort.
Use of fibrin glue (FG) in the fistula tract has been
shown to promote closure of low-output ECFs. As a
noninvasive option, it could avoid the risk of developing
further dehiscence compared to surgical operations. The
application of glue has been reported in recent years for
intestinal fistula in case reports [5, 6] and small series
[7–10]. Commercial fibrin sealants are usually made
from porcine/bovine blood products, whereas autolo-
gous adhesives have potential advantages, such as a low
risk of infection transmission [11] and provision of a
matrix for tissue regeneration [12]. Both are used in
clinical practice, but they have not yet been compared to
fistula sealing.
Our previous study demonstrated that autologous
platelet-rich fibrin glue (PRFG) treatment significantly
decreased time the time to fistula closure and promoted
closure rates. During the follow-up, no treatment-related
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adverse events or severe adverse events were observed
[13]. The previous study was a prospective, nonrando-
mized single-center study. There were several limitations
in the nonrandomized study, which may have led to bias
in our conclusion. Thus, a multicenter, randomized, con-
trolled clinical trial is designed to evaluate the glue ap-
plication in the treatment of patients with low-output
volume ECFs.
Objectives
The objective of this study was to investigate the efficacy
and safety of glue sealing (using PRFG or the commer-
cially available fibrin sealant Yueling™) in the manage-
ment of patients with low-output ECFs.
Trial design
The trial is designed as a multicenter, open-label, ran-
domized, controlled trial with three parallel groups (two
treatment groups and one control group) and a primary
endpoint of fistula closure time during the 14-day treat-
ment period. The randomization will be performed by
Internet-based software with a 1:1:1 allocation. No blind-
ing will take place in this study.
Methods/Design
Participants, interventions and outcomes
Study setting
This is a randomized, open-label, therapeutic trial to in-
vestigate glue-sealing therapy, and the trial is being con-
ducted in nine Chinese academic hospitals. The nine
study sites are distributed in Jiangsu Province, Jiangxi
Province, Shandong Province, Beijing, Henan Province,
Neimenggu Region and Jilin Province, which cover most
parts of East, North, Northeast and Northwest China.
The trial began in March 2014 and is scheduled to be
completed by the end of 2017.
Eligibility criteria
For inclusion, patients must meet the following criteria:
1. Age ≥18 years.
2. Single tubular ECF.
3. Fistula tract length >2 cm.
4. Low output volume (<200 ml/24 h).
5. Written informed consent.
Subjects presenting with any of the indicated general
or indication-specific exclusion criteria will not be in-
cluded in the trial.
The general exclusion criteria include the following:
1. Subject lacks legal capacity.
2. Subject unable to understand the nature, scope,
significance and consequences of this clinical trial.
3. Simultaneously participating in another clinical trial
or participated in any clinical trial involving
administration of acupuncture within 30 days prior
to inclusion.
4. Subject exhibits a physical or psychiatric condition,
which at the investigator’s discretion may put the
subject at risk, may confound the trial results or
may interfere with the subject’s participation in this
clinical trial.
5. Known or persistent abuse of medication, drugs or
alcohol.
6. Current or planned pregnancy or is nursing.
Indication-specific exclusion criteria include the
following:
1. Cancer-infiltrated fistula.
2. Intra-abdominal abscess near the fistulas.
3. Foreign bodies inside the fistula tracts.
4. Distal bowel obstruction.
5. Inflammatory bowel disease.
Interventions
Qualified subjects will randomly be assigned to one of
three study groups: two treatment groups offered autolo-
gous PRFG (Group A) or commercial porcine fibrin seal-
ants (Group B) and one control group with drainage
cessation (Group C).
All groups receive standard of care (SOC) before as-
sessment for inclusion. The SOC comprises supportive
measures to stabilize the fistula patient, including fluid/
electrolyte balance, bowel rest, nutritional replacement,
wound care, and antibacterial therapy in patients with
signs of systemic sepsis or inflammation with pain.
Nasogastric or nasointestinal feeding will be provided
whenever possible; otherwise, parenteral nutrition along
with 0.9 g/24 h somatostatin (Stilamin, Serono,
Switzerland) will be infused intravenously. To assist in
remission of infection, normal saline will be dripped
continuously to rinse the fistula tracts; at the same time,
percutaneous suction drainage of these tracts is con-
ducted. Nursing staff monitor the daily external output
by collecting output volumes. Once the daily fistula vol-
umes decrease to 200 ml, the patients will be evaluated
by the coordinating center.
For patients in Group A, autologous PRFG is prepared
as described previously [14]. The platelet-rich cryoprecipi-
tate and thrombin are obtained from the whole blood of
patients in Group A at least 24 h prior to the start point.
Blood collecting packs, prepared with anticoagulant (cit-
rate phosphate dextrose), are used for the collection of
whole blood (300 to 400 ml). The platelet-rich plasma
(PRP) is separated from the blood by centrifugation at
6 min at 1,000 xg twice at ambient temperature. The PRP
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is transferred to a new pack, and the amount will be deter-
mined by weight. From 40 g PRP, equally transferred to
two new 300 ml empty packs, the euglobulin fraction is
precipitated by dilution with 180 ml citric acid (2.84 mM)
in each pack. After thorough mixing, the pack is centri-
fuged at 3,000 xg for 5 min at 4 °C. The supernatant is re-
moved and the precipitate dissolves in 1.625 ml CaCl2
(0.1 M). The pH is adjusted by the addition of 1.0 ml
NaHCO3 (75 mM) in order to initiate the activation of the
prothrombin to thrombin [15]. The clot formation is ter-
minated after 30 minutes, and the liquid thrombin solu-
tion is removed into microcentrifuge tubes. At the same
time, the cryoprecipitate is produced from the rest of the
plasma, which is frozen at −80 °C for at least 6 h first and
then thawed at 4 °C. After centrifugation at 4,000 rpm/
min for 8 min, the cryoprecipitate is harvested by removal
of the cryoprecipitate-poor plasma. When applied, fibrino-
gen and thrombin are thawed at 37 °C from −20 °C until
recovery of the liquid state.
Patients in Group B receive glue sealing with commer-
cial sealants. The Porcine Fibrin Sealant Kit (Yueling®,
Hangzhou Puji Medical Technology Co. Ltd, Hangzhou,
China) is composed of freeze-dried powder of fibrinogen
and thrombin and of relevant solutions. Stored at 4 °C,
the kit needs to reach room temperature. Then fibrino-
gen (Component I, > 30 mg/ml) is dissolved by sodium
chloride solution (Activator I, 6.0 to 7.0 mg/ml), and
thrombin (Component II, 450 to 850 IU/ml) is dissolved
by calcium chloride solution (Activator II, 35.0 to
45.0 mg/ml).
When receiving glue sealing, the patients in the two
treatment groups will have drainage cessation. Two main
components of FG are placed separately in a double-
syringe system with distal mixing catheter. When ap-
plied, equal amounts of fibrinogen and thrombin are
mixed and the fibrin sealants are to form within 10 sec-
onds. In order to assure total occlusion of the internal
hole, the full length of the fistula tract must be deter-
mined by image examination prior to the procedure or
with assistance of endoscopy [16].
The glue-sealing procedure could be repeated up to
three times within the 14-day glue treatment period. A
repeat sealing could be conducted if the fistula persists
for 5 days after the first procedure. After the 14-day
period, patients who fail to achieve medical closure are
evaluated to further exclude possible factors disturbing
healing, such as infection, foreign body, etcetera. These
unhealed fistulas will either be treated by definitive sur-
gery or continue to be treated conservatively based on
the patient’s best interest and the physicians’ discretion.
Once glue sealing is applied, parenteral nutrition that
provides calories of 20 to 25 kcal/kg is initiated through
the peripheral vein or central venous catheter. Fistula
drainage will be evaluated every day until the drainage
decreases to zero, which is defined as fistula closure
[17]. It also needs confirmation by contrast enhanced
computed tomography at each follow-up visit to verify
the complete closure of internal and external openings
of the fistula tract. When the closure is achieved, a
nasointestinal tube is to be placed and the enteral feed-
ing (2,000 ml/d) is restarted gradually. Other SOC mea-
sures can be conducted when needed.
Outcomes
The primary outcome of the trial is fistula closure time
(defined as the interval between the day of enrollment
and day of fistula closure) during the 14-day treatment
period. Fistula closure is defined as complete closure of
the fistula tract and internal and external openings later,
which will be confirmed by contrast enhanced computed
tomography at each follow-up visit where there is no
drainage or any sign of inflammation [17].
In addition to the primary outcome measure of fistula
closure, secondary outcomes include closure rates up to
14 days, closure rates up to 180 days, fistula recurrence
rates and the incidence of adverse events and severe
adverse events up to 180 days (defined as an event that was
fatal or life-threatening, led to additional hospitalization or
disability or required an intervention to prevent one of
these outcomes).
Participant timeline
All patients with ECFs in each study site receive SOC,
and the fistula output will be evaluated every day. In
case of daily output less than 200 ml, the inclusion cri-
teria will be assessed, and imaging examination will be
performed to exclude abscesses, obstruction, etcetera.
Then participants are randomly allocated to Group A
(autologous fibrin glue), Group B (commercial fibrin
glue) or Group C (drainage cessation). Once enrolled
and allocated to Group A, autologous PRFG needs to be
prepared. The study period is set as 14 days after the
day of enrollment, and fistula drainage will be evaluated
every day. All patients are followed up for at least
180 days. The outpatient visits will be scheduled for
1 month, 3 months and 6 months after enrollment
(Fig. 1).
Sample size
The sample size is to be calculated based on detecting
the minimal, clinically relevant difference in the success
rates of the three arms. Our preliminary study, which
enrolled 145 patients, compared the efficacy of PRFG
application (PRFG group) with drainage cessation (con-
trol group) when low output volume was achieved
(<200 ml/d). During the 28-day treatment period, 77 %
(58/75) of the patients in the PRFG group experienced
fistula closure in comparison to 57 % (40/70) in the
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control group (P = 0.0127) [13]. The unpublished data of
the pilot study demonstrated that closure rates were
80 % (60/75) in the PRFG group and 50 % (35/70) in the
control group during the 14-day observation period.
Due to the above raw data, the closure rates in the two
treatment groups and one control group are assumed to
be 80 % and 50 %, respectively. In this way, 51 patients
per group are needed for this trial based on an alpha of
0.05, with a power of 90 %. Taking into account a drop-
out rate of 10 %, a total sample size of 171 patients
would be included, with 57 participants in each group.
Assignment of interventions
Coordination
A clinical coordinating center in each participating site
is established to identify subject eligibility for the study
and to provide support to investigators and study
personnel throughout the study period. The coordinat-
ing center consists of a principle investigator and a
well-trained study coordinator. Research coordinators
are required to screen all fistula patients in each study
center for eligibility once a day, either the morning or
afternoon. The patient cannot be enrolled until their
eligibility is confirmed by the treating physician. Then,
the study coordinator will obtain written informed con-
sent from the patient. Patients will be consecutively en-
rolled at each of the participating centers whenever a
study coordinator is available for enrollment. Consent
will be obtained from participating clinicians before or
at the time of patient consent.
Allocation
Subjects approved for randomization because they meet
full eligibility criteria will be randomly assigned to one
of the following study groups by using the Internet-
based randomization software RANDOULETTE™ (Insti-
tute of Medical Information Sciences, Biometry and Epi-
demiology, University of Munich). Stratification for age
will be performed, and an equal distribution between
treatment arms (ratio of 1:1:1) will be warranted. The
principle investigator in each coordinating center in-
forms clinicians of the allocation sequence via a central
telephone to ensure concealment.
Blinding
No blinding will take place in this study. Eligible patients
who have given consent will be randomized into any of
the three groups.
Data collection, management and analysis
Data collection and management
A case report form is used to collect the data for each
patient. Assessments are made at the screening period,
inclusion (D0) and on days 1 to 14. Assessments include
fistula assessment (location, output, duration, and length
of fistula tract), monitoring (drainage, catheter, tubes,
and adverse events), laboratory tests (hematology, bio-
chemistry, urinalysis, and pregnancy test at inclusion
only), and microbiology (blood cultures and cultures of
isolates from fistula tracts). Data on adverse events,
compliance and concomitant treatments are collected at

















































Day 1 to 14 Day - 2 to -1 Day 15 







AEs and SAEs AEs and SAEsAEs and SAEs
Fig. 1 Study design. Patients are randomly allocated to group A (autologous fibrin glue), group B (commercial fibrin glue) or group C (drainage
cessation). After glue application or drainage cessation, fistula drainage will be evaluated for 14 days, during which a maximum of three times of
glue sealing will be conducted for patients in groups A and B. Both efficacy and safety outcomes will be assessed during the whole study period.
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the 14th day after randomization. Physicians and re-
search nurses who are not involved in the patients’ care
will assess the outcome.
All documents collected in this study will be stored
safely in confidential conditions. On all study-specific
documents, other than the signed consent, the partici-
pant will be referred to by the study participant number/
code, not by name. Study documentation will be ar-
chived for a period of 5 years after the study.
Statistical analysis
The intention-to-treat approach is utilized to examine
differences in the fistula closure time among the three
groups in the primary analysis by the Pearson χ2 test.
Safety parameters and secondary efficacy parameters will
be analyzed using the Pearson χ2 test and logistic regres-
sion (if necessary). Cox proportional hazards models and
the Kaplan-Meier method will also be applied. Adverse
events will be tabulated according to randomized group




A Data Monitoring Committee (DMC) has been estab-
lished. The DMC is independent of the study organizers.
During the period of recruitment to the study, interim
analyses will be supplied together with any other ana-
lyses that the committee may request. This may include
analyses of data from other comparable trials. The fre-
quency of interim analyses will depend on the judge-
ment of the Chair of the DMC (MY), in consultation
with the study organizers. However, we anticipate that
there might be two interim analyses and one final ana-
lysis. An interim analysis is performed on the primary
endpoint when 50 % of the patients have been random-
ized and have completed the 6-month follow-up. The
trial will not be stopped in case of futility.
Harms
All adverse events will be recorded and closely moni-
tored until resolution or stabilization or until it has been
shown that the study intervention is not the cause of the
event. The chief investigator will be informed immedi-
ately of any serious adverse events and will determine
(in cooperation with the treating physicians) the serious-
ness and causality of these events.
All treatment-related serious adverse events will be re-
corded and reported to the Ethics Committee as part of
the report. Unexpected serious adverse events will be re-
ported to the Ethics Committee within the relevant time
frames. The chief investigator will be responsible for all
adverse event reporting. All site staff will be appropriately
trained in the procedures to follow and the forms to use
during the study protocol prior to study initiation. Regular
central monitoring for all studies and site monitoring, as
determined by the trial-specific risk assessment, will be
used to ensure that all adverse events are identified and
acted on appropriately.
Ethics and dissemination
Ethics committee and regulatory approval
The research team ensures that this study is being con-
ducted in accordance with the principles of the Declar-
ation of Helsinki [18]. The trial will also be conducted in
accordance with both international and Chinese ethical
guidelines for biomedical research involving human sub-
jects [19, 20].
The study protocol, informed consent form, partici-
pant information sheet, and any further patient docu-
ments have been submitted to the Institutional Review
Board of the Ethics Committee of each study site for
written approval. Details of all approving institutional re-
view boards can be found in Additional file 1. Approval
has been obtained from the Ethics Committee for all
substantial amendments to the documents originally
approved.
Protocol amendments
Any modifications to the protocol, including changes of
study objectives, study design, patient population, sam-
ple size, study procedures or significant administrative
aspects, may have impacts on the implementation of the
trial, potential benefits of patients and the patients’
safety. The modifications will require a formal amend-
ment to the protocol. Such amendments will be agreed
on by the sponsor and approved by the Ethics Commit-
tee prior to implementation, and the health authorities
will be notified in accordance with local regulations.
Administrative changes to the protocol are minor cor-
rections that have no effect on the way the study is to be
conducted. These changes will be agreed upon by the
sponsor and will be documented in a memorandum.
The Ethics Committee will be notified of administrative
changes.
Discussion
To our knowledge, this is the first study to evaluate the
safety and efficacy of both autologous and commercial fi-
brin glue sealing for patients with low-output fistulas.
Currently, fibrin glue is indicated only in treating simple
ECFs of low-output volume as a first line therapeutic op-
tion. Therefore, complex or high-output ECFs are ex-
cluded from this study. In addition, this study is designed
as an open-label, three-arm study, with autologous and
commercial fibrin glue in two treatment groups and drain-
age cessation for use as a placebo. Because the autologous
fibrin sealants require blood donation from patients
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themselves, patient blinding cannot be conducted. Further,
there is a possibility that spontaneous closure can be
achieved for fistula patients. Therefore, the control group
is being established for comparison of the efficacy and
safety of the glue application. In this way, this study is
designed as an open-label and three-arm study.
Trial status
The study was conceived and designed in 2014. We are
now recruiting participants.
Additional file
Additional file 1: Ethical bodies approved the study. Details for the
approving institutional review boards. (DOCX 67 kb)
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